To The Moon

  • Home
  • News
  • TigerAI
Log In Sign Up

Trump presses to cut prices, weight loss drug companies' stock prices fluctuate

Trump pressured to cut prices, and the stock prices of diet drug companies Eli Lilly and Novo Nordisk fluctuated, the precious metals sector continued its upward trend

0 followers
Login to post
  • NewsNews
  • PostsPosts
  • SelectionSelection
    • 美股异动丨礼来、诺和诺德盘初跌超4%,特朗普称减肥药价格将大幅下降

      2025-10-17
    • 开盘|美股普跌,甲骨文跌超4%,诺和诺德跌超4%

      2025-10-17
    • 诺和诺德(NVO.US)、礼来(LLY.US)美股盘前跌约3.7%此前特朗普称减肥药物价格将下调。

      2025-10-17
    • 礼来股票在法兰克福下跌4.4%;特朗普表示竞争对手诺和诺德的减肥药价格将降低

      2025-10-17
    • 诺和诺德欧股跌5%

      2025-10-17
    • 诺和诺德欧股股价下跌5%此前特朗普称减肥药物价格将下调。

      2025-10-17
    • 美股夜盘|特朗普施压降价!减肥药企礼来、诺和诺德齐跌逾3%;贵金属板块延续升势

      2025-10-17
    • 特朗普表示减肥药物Ozempic(司美格鲁肽)的价格可能降至每月仅150美元后礼来(LLY.US)以及诺和诺德(NVO.

      2025-10-17
    • 特朗普称减肥药物价格将下调,将会进行GLP减肥药谈判

      2025-10-17
    • HawSHawS
      ·2025-10-20

      Why the Market Is "Wrongly Killing" HIMS After the Trump News

      The market panicked after President Trump vowed to slash weight-loss drug prices to $150. In the chaos, $Hims & Hers Health Inc.(HIMS)$  stock plummeted, with investors assuming its business was impacted. Hims is a telehealth platform, not just a compounder. They are a reseller. A massive price drop will lead to a massive increase in sales volume. The single biggest barrier to these drugs is the $1,000+ price tag. If that barrier is removed, millions of new customers will flood the market. Where will they go? They will seek the easiest, most frictionless platform. Hims, with its powerful brand and simple telehealth service, is perfectly positioned to capture this enormous new wave of demand. Even if the profit per prescription shrink
      看2.49K回复6
      点赞8
      编组 21备份 2Share
      Report
      Why the Market Is "Wrongly Killing" HIMS After the Trump News
    • HawSHawS
      ·2025-10-20

      Why the Market Is "Wrongly Killing" HIMS After the Trump News

      The market panicked after President Trump vowed to slash weight-loss drug prices to $150. In the chaos, $Hims & Hers Health Inc.(HIMS)$  stock plummeted, with investors assuming its business was impacted. Hims is a telehealth platform, not just a compounder. They are a reseller. A massive price drop will lead to a massive increase in sales volume. The single biggest barrier to these drugs is the $1,000+ price tag. If that barrier is removed, millions of new customers will flood the market. Where will they go? They will seek the easiest, most frictionless platform. Hims, with its powerful brand and simple telehealth service, is perfectly positioned to capture this enormous new wave of demand. Even if the profit per prescription shrink
      看2.49K回复6
      点赞8
      编组 21备份 2Share
      Report
      Why the Market Is "Wrongly Killing" HIMS After the Trump News
Terms and Conditions Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin. Email: uservice@ttm.financial